6-APDB (6-(2-aminopropyl)-2,3-dihydrobenzofuran), also known as 4-desoxy-MDA or 3-desoxy-MDA, is a substituted benzofuran entactogen closely related to MDA and to the APB series. The "6" position isomer has been the primary focus of research, though 4-APDB and 5-APDB also exist. Unlike 5-APB and 5-MAPB which feature an unsaturated benzofuran ring, 6-APDB contains a dihydrobenzofuran scaffold — structurally very close to MDA with the oxygen of the methylenedioxy bridge replaced by a single methylene oxygen in a 2,3-dihydrobenzofuran ring.
The experiential profile is described as strongly empathogenic with significant stimulant character, closely resembling MDA but with somewhat less psychedelic visual intensity and a longer duration than MDMA. It emerged in the novel psychoactive substance market alongside the APB series and carries the same range of serotonergic risks — neurotoxicity potential, cardiovascular strain, and cardiac 5-HT2B agonism with repeated use.
Safety at a Glance
High Risk- Use Marquis reagent (expected: orange to black/purple), Mecke (blue-green), and Simon's (negative, as 6-APDB is a pri...
- Threshold: 30–45 mg | Common: 45–75 mg | Strong: 75–100 mg
- Toxicity: Acute Toxicity As a serotonin-releasing amphetamine-class compound, 6-APDB's acute risks parallel those of MDA: hyper...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from 6-APDB is a medical emergency primarily involving cardiovascular and neur...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 8 hrsHow It Feels
The onset of 6-APDB is gradual and understated. An hour to ninety minutes after ingestion, a faint warmth begins to gather in the chest. Emotional registers soften subtly, and there is a growing sense of ease and openness that arrives without fanfare. The body relaxes gently, tension releasing from the shoulders and jaw. Unlike its more forceful relatives, 6-APDB does not announce itself with euphoric waves or dramatic perceptual shifts. Instead, it quietly adjusts the emotional thermostat upward by a few degrees.
As the effects develop, a mild empathogenic quality establishes itself. Social interactions feel slightly warmer and more genuine. There is an increased willingness to listen, to empathize, and to share, but these qualities feel like enhancements of existing tendencies rather than departures from normal behavior. Touch sensitivity increases modestly, and music takes on a subtle emotional richness. The stimulant component is minimal to absent; the body feels relaxed and comfortable rather than energized. There is little desire to dance or move vigorously, and the experience favors quiet intimacy over active socializing.
At the peak, roughly two to three hours in, 6-APDB maintains its characteristic restraint. The emotional warmth is genuine but mild, a pleasant glow rather than an overwhelming flood. There may be subtle visual changes: slightly enhanced color saturation, a gentle softening of edges. The headspace is calm and clear, undisturbed by the cognitive disruption that accompanies stronger empathogenic compounds. Physical side effects are minimal: modest jaw tension, slight pupil dilation, mild warmth. The experience is comfortable and benign, well-suited to reflective conversation or simply sitting with another person in companionable warmth.
The decline begins around four to five hours in and is as gentle as the onset. The mild warmth gradually recedes, and baseline emotional functioning returns without any jarring transition. The comedown is notably mild compared to stronger empathogenic compounds. There may be slight fatigue and a touch of emotional quietness the following day, but the serotonergic debt is small, proportional to the modest effects that generated it. The total duration of five to seven hours passes comfortably, and the experience is often described as pleasant, gentle, and somewhat forgettable, a mild exploration of warmth without the costs that usually accompany it.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(22)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Brain zaps— Brain zaps are sudden, brief, electrical shock-like sensations that originate in the head and someti...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(10)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
Cognitive(21)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(2)
- Memory replays— Memory replays are vivid, multisensory re-experiences of past events that go far beyond normal recal...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
6-APDB acts as a releasing agent and triple reuptake inhibitor of serotonin, dopamine, and noradrenaline. The serotonergic action predominates, consistent with its empathogenic character. Its structural relationship to MDA suggests a similar receptor pharmacology, including potential 5-HT2A and 5-HT2B agonism.
Structural Relationship to MDA
The dihydrobenzofuran scaffold of 6-APDB places it structurally between MDA (3,4-methylenedioxy amphetamine) and the desoxy phenethylamines. The pharmacological consequences of this structural difference include modest shifts in receptor selectivity, but the overall profile — triple monoamine activity with serotonin dominance — is retained from the MDA template.
Pharmacokinetics
6-APDB is orally active at doses of approximately 40–90 mg. Onset is 60–90 minutes, with peak effects at 2–4 hours and a total duration of 5–8 hours. Metabolism occurs via cytochrome P450 enzymes; active metabolites may contribute to effects and to oxidative stress on serotonergic neurons.
Detection Methods
Standard Drug Panel Inclusion
6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) is a benzofuran-class entactogen that is not detected on standard 5-panel or 10-panel immunoassay drug screens. Some MDMA/amphetamine immunoassays may show partial cross-reactivity due to the aminopropyl side chain, but this varies by manufacturer and cannot be relied upon. Extended panels do not typically include benzofuran compounds.
Urine Detection
6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) can be detected in urine for approximately 2 to 4 days after use. Metabolism involves hepatic oxidation, O-dealkylation, and conjugation. The metabolic pathway has some overlap with MDMA metabolism due to the structural analogy, but the benzofuran ring system produces distinct metabolites. Standard immunoassay screens are unreliable for detecting benzofuran compounds.
Blood and Saliva Detection
Blood detection windows for 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) are approximately 12 to 48 hours. Oral fluid detection is possible for 24 to 48 hours. These modalities are used primarily in emergency medicine and forensic toxicology settings rather than routine drug testing.
Hair Follicle Detection
Hair follicle testing for 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) requires specialized LC-MS/MS analysis and is not included in standard commercial hair testing panels. Detection in hair is possible for up to 90 days with appropriate analytical methods and reference standards.
Confirmatory Testing
LC-MS/MS is the gold standard for confirming the presence of 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran). This method can distinguish benzofuran compounds from MDMA, MDA, and other entactogens based on molecular weight, fragmentation patterns, and retention time. GC-MS is also effective. Reference standards are essential for positive identification.
Reagent Testing
Marquis reagent typically produces a dark purple to black color with 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran), similar to the reaction seen with MDMA and MDA (due to the oxygen-containing ring system). Mecke reagent produces a blue-green to dark blue reaction. Simon's reagent helps differentiate primary amines (5-APB, 6-APDB: negative) from secondary amines (5-MAPB: positive). Mandelin may show an orange-brown color. The combination of reagent responses can narrow identification but cannot conclusively distinguish benzofurans from methylenedioxy compounds.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Development
6-APDB emerged from the systematic exploration of dihydrobenzofuran analogs of MDA and MDMA in clandestine and research chemistry during the 2000s–2010s. Its existence as the "desoxy" variant of MDA (removing one oxygen from the methylenedioxy group) was documented in pharmacological literature describing structure-activity relationships in the substituted amphetamine class.
Market Appearance
Like 5-APB and 5-MAPB, 6-APDB was sold in the UK novel psychoactive substance market during 2010–2012, typically marketed under benzofuran branding. Community reports from this period characterize it as the most stimulant-intense of the APB/APDB series.
Legal Status
6-APDB is controlled in the UK as a Class B substance and in many European jurisdictions. In the United States it falls under Federal Analogue Act provisions as an MDA analogue.
Harm Reduction
Reagent Testing
Use Marquis reagent (expected: orange to black/purple),Mecke (blue-green), andSimon's (negative, as 6-APDB is a primary amine like MDA) to confirm identity.
Dose and Timing
- Threshold: 30–45 mg |Common: 45–75 mg |Strong: 75–100 mg
- The stimulant character is stronger than MDMA or 5-APB — plan the experience during daytime or early evening to avoid disrupted sleep.
- Do not redose; the stimulant aftereffects are prolonged and a redose primarily extends the negative physical load.
Neurotoxicity Risk Reduction
Given the MDA structural analogy, conservative practices are especially important:
- Minimum 3-month interval between uses
- Antioxidant pre- and post-loading (alpha-lipoic acid, NAC, vitamin C)
- Strict temperature management; avoid warm environments during peak effects
- Adequate hydration with electrolytes
Dangerous Combinations
- MAOIs — fatal serotonin syndrome
- Stimulants — amplified cardiovascular and neurotoxic risk
- Alcohol — dehydration, masked hyperthermia
- Lithium — CNS and seizure risk
Toxicity & Safety
Acute Toxicity
As a serotonin-releasing amphetamine-class compound, 6-APDB's acute risks parallel those of MDA: hyperthermia, hyponatremia, serotonin syndrome, and cardiovascular strain. Hyperthermia is the most immediately life-threatening acute event, particularly in warm or physically active settings.
Neurotoxicity
6-APDB's structural analogy to MDA — the most robustly neurotoxic ring-substituted amphetamine in animal models — raises significant concern about serotonergic axon terminal damage with repeated use. The mechanism involves reactive quinone metabolites generated by CYP450 N-demethylation and ring oxidation that produce oxidative damage to the serotonin system. Hyperthermia dramatically amplifies this toxicity.
Cardiovascular Risks
Norepinephrine and dopamine release produce elevated heart rate and blood pressure. Combined with any direct 5-HT2B agonism, chronic use poses both acute cardiovascular strain and potential long-term valvular risks.
Contraindications
- MAOIs — absolute contraindication (serotonin syndrome)
- Structural cardiac disease, hypertension, or arrhythmias
- Personal or family history of psychosis or mania
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from 6-APDB is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | with prolonged and repeated use |
| Half | 21-30 days |
| Zero | 2-3 months |
Cross-tolerances
Legal Status
Australia and New Zealand: Certain countries contain a "substantially similar" catch-all clause in their drug law, such as New Zealand and Australia. This includes 6-APDB as it is similar in chemical structure to the class A drug MDA, meaning 6-APB may be viewed as a controlled substance analogue in these jurisdictions.
Canada: 6-APDB is Schedule III in Canada as it is an analogue of MDA. The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.
France: 6-APDB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.
Germany: 6-APDB is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Italy: 6-APDB is a prohibited substance in Italy.
Sweden: 6-APDB is prohibited in Sweden as a "health hazard" as of 2009.
Switzerland: 6-APDB is a controlled substance specifically named under Verzeichnis E.
United Kingdom: On June 10, 2013, 6-APDB and a number of analogues were classified as Temporary Class Drugs in the U.K. following an ACMD recommendation. On March 5, 2014, the U.K. Home Office announced that 6-APDB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.
United States: 6-APDB is unscheduled in the United States. It may be considered an analog of MDA (which is a Schedule I drug under the Controlled Substances Act). As such, the sale and possession for the purposes of human consumption or could be prosecuted as crimes under the Federal Analog Act.
Responsible use
Entactogens
MDA
Stimulants
Phenethylamines
Benzofuran
6-APDB (Wikipedia)
6-APDB (Isomer Design)
Experience Reports (1)
Tips (3)
Start low with 6-APDB and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Monitor your heart rate and blood pressure when using 6-APDB. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
Stay hydrated while using 6-APDB. Stimulants increase heart rate and body temperature while suppressing thirst signals. Sip water regularly, roughly 250-500ml per hour, more if dancing or in hot environments.
See Also
References (5)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- PubChem: 6-APDB
PubChem compound page for 6-APDB (CID: 192599)
pubchem - 6-APDB - TripSit Factsheet
TripSit factsheet for 6-APDB
tripsit - 6-APDB - Wikipedia
Wikipedia article on 6-APDB
wikipedia